Horizon 1 1 17 ACLN : Articles dans des revues avec comité de lecture non répertoriées par l'AERES American Journal of Tropical Medicine and Hygiene 1017-1018 SERPENT MORSURE VENIN TRAITEMENT MEDICAL ANTICORPS ENFANT ADULTE ESSAI CLINIQUE FAV-AFRICA EFFET INDESIRABLE AFRIQUE SUBSAHARIENNE CAMEROUN 1999 fdi:010021757 ENG American Journal of Tropical Medicine and Hygiene 0002-9637 6 https://www.documentation.ird.fr/hor/fdi:010021757 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_7/b_fdi_55-56/010021757.pdf 61 Horizon (IRD) A clinical trail was conducted in 2 health centers in northern Cameroon to assess the safety and efficacy of a new polyvalent antivenom composed of higly purified and pasteurized F(ab')2 (FAV-Africa). Forty-six patients with objective signs of envenomation, including 67% with hemorrhage, were included in the study. Each patient received at least 20 ml of FAV-Africa by direct, slow intravenous injection ; 172 10-ml ampules were administered. All patients were clinically cured after treatment. Two patients (4.3%) showed minor immediate adverse events that may have been related to FAV-Africa (induration, light-headedness) ; no other treatment-related adverse event occurred. No patient had serum sickness. This trial confirms the safety of FAV-Africa administered by intravenous injection and its efficacy in the treatment of snake envenomations in sub-Sahara Africa. (Résumé d'auteur) 050MEDECI